Lineage, Inc. LINE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 32.1%-0.6pp | 32.1%-0.9pp | 32.2%-0.9pp | 32.3%-0.7pp | 32.7%-0.2pp | |
| Operating margin | 3%+10.7pp | 3.4%+10.1pp | 1.7%+7.0pp | -8.6%-14.8pp | -7.7%-14.5pp | |
| Net margin | -2.8%+8.9pp | -2%+10.5pp | -3.3%+8.8pp | -10.6%-6.9pp | -11.8%-9.2pp | |
| Returns | ||||||
| Return on equity | -1.8%+7.0pp | -1.3%+8.4pp | -2%+6.7pp | -8.3%-4.7pp | -8.8%-6.5pp | |
| Return on invested capital | 1%— | 1.1%+3.4pp | 0.6%— | -2.8%— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.3×— | 0.3×0.0× | 0.3×— | 0.3×— | —— | |
| Liquidity | ||||||
| Current ratio | 0.8×-0.1× | 0.8×-0.1× | 1×-0.1× | 1×-0.1× | 1×— | |
| Leverage | ||||||
| Debt-to-equity | 1×+0.2× | 1×+0.2× | 0.9×+0.2× | 0.9×-1.4× | 0.8×— | |
| Net debt / EBITDA | 7.5×-7.4× | 7.4×-5.9× | 7.9×-4.1× | 18×+8.2× | 15×— | |
| Per Share | ||||||
| Book value per share | $35.63-5.4% | $36.17-20.0% | $36.77-14.5% | $37.72+25.3% | $37.66+8.8% | |
| Valuation | ||||||
| Market capitalization | $7.44B-44.4% | $7.99B-40.3% | $8.84B— | $10.58B— | $13.38B— | |
| Price / sales | 1.4×-1.1× | 1.5×-1.0× | 1.6×— | 2×— | 2.5×— | |
| Price / book | 0.9×-0.6× | 1×-0.6× | 1.1×— | 1.2×— | 1.6×— | |
| EV / EBITDA | 14.5×-28.9× | 14.9×-24.4× | 16.7×— | 42.9×— | 43.4×— | |
| Dividend yield | 7.2%+5.3pp | 6.7%+5.0pp | 5.6%— | 3.6%— | 1.9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Lineage, Inc.'s profit margins?
- Lineage, Inc. (LINE) runs a 32.1% gross margin and a 3.0% operating margin, with a -2.8% net margin.
- Where do Lineage, Inc.'s ratios come from?
- Every ratio is computed from Lineage, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
